Parkinsonian Disorder is a neurodegenerative disorder characterized by progressive degeneration and death of neurons (nerve cells) in certain brain regions. It can cause trembling, muscle stiffness, slowness of movement, difficulty with balancing or walking, and other motor problems. This disorder is commonly associated with aging and is oftentimes referred to as Parkinson’s disease. The primary features of Parkinsonian Disorder are caused by the gradual death of dopamine-generating neurons in the substantia nigra, a brain region located in the midbrain. As a result of this cell loss, patients with Parkinson’s are unable to generate adequate amounts of dopamine to stimulate the areas of the brain that control movement and balance. There is currently no cure for Parkinsonian Disorder, but there are a variety of treatments available that can help slow its progression and improve the quality of life of those afflicted. These include medications that increase dopamine levels in the brain as well as physical and occupational therapy programs that teach the patient how to optimize movement and maintain a quality of life. In some cases, a surgical procedure known as Deep Brain Stimulation (DBS) may also be used to improve motor symptoms. The symptoms of Parkinsonian Disorder can be very disabling and dramatically affect a person's ability to function and interact with family and friends. Because of this, it is important that individuals affected by this condition are provided with a multidisciplinary approach to treatment that assesses both their physical and psychological condition. This holistic approach may include cognitive-behavioral therapy to help manage emotions, family support, and/or improved communication reach out to a specialized counselor or therapist to further address the emotional aspect of this condition. Ultimately, Parkinsonian Disorder can take a dramatic toll on the quality of life for those affected. Early intervention and education is key, as identifying and managing the condition as early as possible is essential in improving care and diminishing its effects.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom